訊聯細胞智藥股份有限公司 Approved
最後更新時間 2025/07/08 , 02:32 AM
最後更新時間 2025/07/08 , 02:32 AM
負責人
Cai,Zheng-Xian
統一編號
90272474
成立日期
2022/06/15
資本額
NT$1,000,000,000
實收資本額
NT$700,000,000
股票代號
7808
電話
02-27951777#1028
地址
1F, No. 28, Ln. 36, Sinhu 1st Rd., Neihu Dist., Taipei City, 114, Taiwan
網站
董監事
姓名 職稱 持有股份 代表法人
Cai,Zheng-Xian Chairman 32.64% Bionet Corporation(Bionet Corp.)
Zhang,Cui-Ru Director 5.78% GENETICS GENERATION ADVANCEMENT CORP. (GGA CORP.)
Liang,Yu-Lun Director 1.43% CHIEN HSIN TRADING CO., LTD.
Zhang,Wen-Zheng Director 0.88%
Sheng,Bao-Xi Director 1.43% Baolei Co. Ltd.
Lin,Pi-Rong Independent Director 0.00%
Zhuang,Fu-Jun Independent Director 0.00%
LING STEVEN DEE Independent Director 0.00%
Lin,Kun-Ming Independent Director 0.00%
營業項目
  • Other Human Health Activities Not Elsewhere Classified(869913)
  • Other Human Health Activities Not Elsewhere Classified(869914)
  • 公司歷程
  • Change Capital to 1,000,000,000
    2024/04/24
  • 員工人數
    下載完整報告查看完整數據
    財務報表
    項目 2024 2023
    Operating income 81,319 5,369
    Operating cost 79,301 3,571
    Profit (loss) of initial recognition of biological asset and agricultural products - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - -
    Operating gross profit (loss) 2,018 1,798
    Unrealized profit (loss) on sales of goods - -
    Realized profit (loss) on sales of goods - -
    Operating gross profit (loss), net 2,018 1,798
    Operating expenses 101,381 41,056
    Other gain (loss), net - -
    Operating profit (loss) -99,363 -39,258
    Non-operating income and expenses 13,105 1,920
    Net profit (loss) before tax -86,258 -37,338
    Income tax expense (benefits) 0 0
    Net profit (loss) of ongoing business for the current period -86,258 -37,338
    Profit (loss) of closed units - -
    Profit (loss) of non-jointly controlled equity before merger - -
    Net profit (loss) for the current period -86,258 -37,338
    Other comprehensive profit (loss), net -5,080 -
    Comprehensive net profit and loss of non-jointly controlled equity before merger - -
    Total comprehensive profit and loss for the current period -91,338 -37,338
    Net profit (loss) attributable to owners of parent company - -
    Net profit (loss) form equity attributable to former owner of business combination under common control - -
    Net profit (loss) attributable to non-controlling interests - -
    Comprehensive profit (loss) attributable to owners of parent company - -
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - -
    Comprehensive profit (loss) attributable to non-controlling interests - -
    Basic earnings per share (yuan) -1 -2
    項目 2024 2023
    Net cash inflow (outflow) from operating activities - -
    Net cash inflows (outflows) from investing activities - -
    Net cash inflow (outflow) from financing activities - -
    Effect of Exchange Rate Changes on Cash and Cash Equivalents - -
    Increase (decrease) in cash and cash equivalents in the current period - -
    Beginning balance of cash and cash equivalents - -
    Ending balance of cash and cash equivalents - -
    項目 2024 2023
    Current asset 1,274,970 528,346
    Non-current asset 75,052 11,835
    Total asset 1,350,022 540,181
    Current liability 53,702 12,088
    Non-current liability - -
    Total liability 53,702 12,088
    share capital 700,000 450,287
    Equity - secruity token - -
    capital reserve 735,095 125,243
    retained earning -133,695 -47,437
    Other equity -5,080 -
    Treasury stock - -
    Total equity attributable to owners of parent company - -
    Equity attributable to former owner of business combination under common control - -
    Equity attributable to non-controlling interest before business merger under common control - -
    Non-controlling interests - -
    Total Equity 1,296,320 528,093
    Share capital awaiting retirement (unit: share) 0 0
    Issued shares of advance equity (unit: shares) 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0
    Net asset value per share 18 11
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • ExoTear
  • Metasome美達頌
  • 沛芮兒
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
    勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。